Clinical Effects of Activated Charcoal Unavailability on Treatment Outcomes for Oral Drug Poisoned Patients

Sohyun Park,1 Hui Jai Lee,1 Jonghwan Shin,1 Kyoung Min You,1 Se Jong Lee,2 and Euigi Jung3

1Department of Emergency Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea
2Department of Emergency Medicine, Sejong General Hospital, Bucheon, Gyeonggi-do 14754, Republic of Korea
3Department of Emergency Medicine, Central Veterans Hospital, Seoul 05368, Republic of Korea

Correspondence should be addressed to Hui Jai Lee; emdrlee@gmail.com

Received 26 May 2018; Revised 27 August 2018; Accepted 19 September 2018; Published 3 October 2018

Background. Activated charcoal is the most frequently and widely used oral decontaminating agent in emergency departments (EDs). However, there is some debate about its clinical benefits and risks. In Korea, activated charcoal with sorbitol was unavailable as of the mid-2015, and our hospital had been unable to use it from September 2015. This study examined the differences of clinical features and outcomes of patients during the periods charcoal was and was not available.

Methods. We retrospectively reviewed the electronic medical records of patients who had visited an urban tertiary academic ED for oral drug poisoning between January 2013 and January 2017.

Results. For the charcoal-available period, 413 patients were identified and for the charcoal-unavailable period, 221. Activated charcoal was used in the treatment of 141 patients (34%) during the available period. The mortality rates during the available and unavailable periods were 1.9 and 0.9%, respectively (p = 0.507). There was also no interperiod difference in the development of aspiration pneumonia (9.9 versus 9.5%, p = 0.864), the endotracheal intubation rate (8.4 versus 7.2%, p = 0.586), and vasopressor use (5.3 versus 5.0%, p = 0.85). Intensive care unit (ICU) admission was higher in the unavailable period (5.8 versus 13.6%, p = 0.001). ICU days were lower in the unavailable period (10 [4.5-19] versus 4 [3-9], p = 0.01). Hospital admission (43.3 versus 29.9%, p = 0.001) was lower in the unavailable period. Conclusions. In this single center study, there appeared to be no difference in mortality, intubation rates, or vasopressor use between the charcoal-available and charcoal-unavailable periods.

1. Introduction

Activated charcoal is the gastrointestinal (GI) decontaminating agent that had been regarded as an essential first-line therapy for acute-poisoning patients. However, few studies have shown clinical improvement of poisoned patients who had been treated using activated charcoal. Indications of activated charcoal are decreasing. The indications and use of activated charcoal as a decontamination procedure actually have been declining over the years [1–3]. American poison centers reported a sharp drop between 1995 and 2016, from 7.7% of all exposures to 1.9%, respectively [4]. The most recent guidelines emphasize that activated charcoal should not be used routinely [5]. However, there are as yet no specific and detailed guidelines on the use of activated charcoal. Indeed, there are significant variations in the use of activated charcoal among clinicians [6, 7].

In Korea, premixed activated charcoal with sorbitol had been the only available form of activated charcoal [8]. Due to importation issue, its use was discontinued from 2015. As a result, activated charcoal with sorbitol has been unavailable at our hospital from September of that year. In the present study, we evaluated the clinical outcome differences between the charcoal-available and charcoal-unavailable periods.

2. Materials and Methods

2.1. Study Design and Setting. This study was conducted in an urban academic teaching hospital with an annual emergency department (ED) census of 58000. A retrospective chart
review was conducted for the period from January 2013 to January 2017. Patients whose ICD-10-based ED diagnosis was poison-related were selected from electronic medical records. Those who had visited the ED with oral drug overdose, were over 18 years old, and had been exposed within the previous 24 hours were included. Those aged under 18 years, pregnant women, and those suffering caustic ingestion or heavy metal poisoning were excluded.

The subjects’ age, sex, clinical parameters such as vital signs, Glasgow Coma Scale (GCS), underlying diseases, laboratory results, and clinical outcomes were collected. Aspiration pneumonia was defined as newly developed lung lesions on chest X-ray or computed tomography and worsening of respiratory symptoms within 48 hours of admission [9, 10].

This study was approved by the Institutional Review Board (IRB) of the study hospital (IRB no. 20170626/30-2017-15/073). Informed consent was waived by the IRB.

2.2. Statistical Analysis. Mortality, endotracheal intubation and vasopressor use, development of aspiration pneumonia, intensive care unit (ICU) admission, and hospital admission were evaluated as clinical outcomes.

A subgroup analysis was performed for factors that can affect the clinical efficacy of activated charcoal based on previous studies [11–13]. Moreover, we defined the conditions under which activated charcoal can be beneficial: (1) patient presents within 2 hours of ingestion, (2) GCS 13-15 on arrival, and (3) potentially toxic ingestion (excluding ingestion of less toxic substance such as benzodiazepines and sedatives, as well as cases of ingestion of relatively small amounts) [5]. Two board-certified emergency physicians decide whether there is potential toxic exposure or not.

The Shapiro-Wilk test was used to evaluate the normality of the continuous variables, which were expressed as a mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables were summarized by frequency according to the corresponding percentage and compared using the chi-square test or Fisher’s exact test as appropriate.

All of the analyses were performed with SPSS 22 (IBM, Armonk, New York, USA). A p value less than 0.05 was considered to indicate statistical significance.

3. Results

3.1. Characteristics of the Patients. In this retrospective cohort study, we identified 634 patients who met the study criteria. Four hundred and thirteen (413) patients were managed during the activated charcoal-available period and 221 during the activated charcoal-unavailable period (Table 1). Activated charcoal was used in the treatment of 141 patients (34.0%) during the activated charcoal-available period. No enrolled patient received multiple-dose charcoal.

There was no interperiod difference in patient age, sex, medical history, or vital signs. There were statistical interperiod differences in some initial laboratory values (sodium, creatine kinase-MB, troponin I, and activated partial thromboplastin time) (Table 1), though they were minimal and not clinically significant. Gastric lavage was more frequently performed in the activated charcoal-available period (26.4%) than in the activated charcoal-unavailable period (10%) (p < 0.001). The ingested toxic substances of both groups are presented in Table 2.

3.2. Charcoal Availability and Clinical Outcome. There were no differences in the incidence of aspiration pneumonia, the rate of intubation, vasopressor use, or mortality between the charcoal-available and charcoal-unavailable periods (Table 3).

The rates of hospital admission (43.3 versus 29.9%, p < 0.001) and ICU admission (5.8 versus 13.6%, p < 0.001) were higher in the charcoal-unavailable period; however, the number of ICU days was lower and the total hospital stay was shorter (Table 3 and Figure 1).

3.3. GCS and Clinical Outcomes according to Charcoal Availability. According to the GCS levels, there were no interperiod differences in aspiration pneumonia, intubation, vasopressor use, or mortality. In the charcoal-unavailable period, hospital admission was less common and the rate of ICU admission was higher for patients with preserved mental status (GCS 13-15) (Table 3). During the charcoal-available period, both hospital admission and ICU admission were more common for charcoal-administered patients (Table 4).

3.4. Single- and Multiple-Drug Ingestions and Clinical Outcome according to Activated Charcoal Availability. Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period were observed among the single-drug-poisoned patients. The other clinical outcomes did not differ between the periods for either single- or multiple-drugs-poisoned patients (Table 5).

3.5. Presenting Time and Clinical Outcome according to Activated Charcoal Availability. Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period also were observed among the patients with a time delay of more than 1 hour from ingestion to ED visit (Table 6). The other clinical outcomes did not differ between the periods. During the charcoal-available period, intubations were more commonly conducted for patients who had arrived at the ED within 1 hour and received activated charcoal (11.4 versus 9.1%, p = 0.015) (Table 6).

3.6. Clinical Outcomes of Patients Who May Benefit from Activated Charcoal. Twenty-three patients and 17 patients were identified during the charcoal-available and charcoal-unavailable periods, respectively. Activated charcoal was used for 12 patients (52.1%) during the charcoal-available period. There were no differences in clinical outcomes between the periods (Table 7) (Supplemental Table 2).

3.7. Mortality Cases. Among the mortality cases, only one patient visited within 2 hours of exposure. His age was 92 and he died due to aspiration pneumonia. Charcoal was not used, because of decreased consciousness, sedative poisoning, and high risk of respiratory complication. He died from respiratory complications 18 days from ED visit.
### Table 1: Patient characteristics.

|                              | Charcoal-available period (n=413) | Charcoal-unavailable period (n=221) | p-value |
|------------------------------|-----------------------------------|-------------------------------------|---------|
| Age, median (IQR)            | 41 (28-58)                        | 43                                  | 0.267   |
| Male, n (%)                  | 148 (35.8%)                       | 77                                  | 0.803   |
| Medical History              |                                   |                                     |         |
| Hypertension, n (%)          | 72 (17.4%)                         | 32 (14.5%)                          | 0.339   |
| Diabetes mellitus, n (%)     | 40 (9.7%)                          | 19 (8.6%)                           | 0.653   |
| Multiple drug ingestion      | 242 (58.6%)                        | 119 (53.8%)                         | 0.250   |
| Vital signs                  |                                   |                                     |         |
| Mean blood pressure (mmHg), median (IQR) | 93 (79-103) | 94 (77-107) | 0.495   |
| Heart rate (/min), median (IQR) | 90 (79-100)  | 87 (76-103)  | 0.258   |
| Respiratory rate (/min), median (IQR) | 20 (18-20)  | 20 (18-20) | 0.168   |
| Body temperature (°C), median (IQR) | 36.2 (36.0-36.6) | 36.4 (36.0-36.7) | 0.102   |
| GCS, median (IQR)            | 14 (11-15)                         | 14 (10-15)                          | 0.971   |
| Laboratory results           |                                   |                                     |         |
| WBC (x10^3/μL), median (IQR) | 7.55 (5.76-10.19)                 | 7.44 (5.96-9.82)                    | 0.996   |
| Hemoglobin (g/dL), median (IQR) | 13.5 (12.6-14.6)                   | 13.4 (12.2-14.6)                    | 0.374   |
| Platelet (*1000/μL), median (IQR) | 249 (205-299.5) | 249 (202-298.5) | 0.970   |
| Sodium (mmol/L), median (IQR) | 139.1 (137.3-140.9)               | 138.6 (136.6-140.6)                | 0.046   |
| Potassium (mmol/L), median (IQR) | 3.8 (3.5-4.12)                   | 3.8 (3.5-4.00)                     | 0.429   |
| Total CO₂ (mmol/L), median (IQR) | 22.8 (20.90-26.26)              | 22.3 (20.15-26.50)                  | 0.082   |
| BUN (mg/dL), median (IQR)    | 12 (9-16)                         | 13 (11-16)                          | 0.167   |
| Creatinine (mg/dL), median (IQR) | 0.74 (0.61-0.89)                | 0.74 (0.65-0.91)                    | 0.242   |
| AST (IU/L), median (IQR)     | 25 (19-37)                        | 25 (19-28)                          | 0.880   |
| ALT (IU/L), median (IQR)     | 15 (10-25)                        | 15 (10-29)                          | 0.772   |
| CRP (mg/dL), median (IQR)    | 0.08 (0.03-0.24)                  | 0.07 (0.02-0.26)                    | 0.501   |
| CK (IU/L), median (IQR)      | 97 (69-151)                       | 96 (68-159)                         | 0.838   |
| CK-MB (ng/mL), median (IQR)  | 0.5 (0.5-1.1)                     | 0.9 (0.6-2.1)                       | < 0.001 |
| Troponin I (ng/mL), median (IQR) | 0.04 (0.04-0.04)                | 0.02 (0.01-0.02)                    | < 0.001 |
| aPTT (seconds), median (IQR) | 25.9 (23.0-28.7)                 | 27.2 (25.0-30.3)                     | < 0.001 |
| PT (INR), median (IQR)       | 1.06 (1.01-1.11)                 | 1.06 (1.01-1.12)                    | 0.836   |
| Gastric lavage, n (%)        | 109 (26.4%)                       | 22 (10%)                            | < 0.001 |
| Activated charcoal, use n (%)| 141 (34.1%)                       | 0 (0%)                              | < 0.001 |
| SOFA score*                  | 6 (4-7)                           | 5 (3-6)                             | 0.153   |

GCS: Glasgow Coma Scale; WBC: white blood cells; BUN: blood urea nitrogen; AST: aspartate transaminase; ALT: alanine aminotransferase; CRP: C-reactive protein; CK: creatine kinase; CK-MB: creatine kinase-MB; aPTT: activated partial thromboplastin time; PT: prothrombin time; SOFA: sequential organ failure assessment.

* Only for ICU patients.

### Table 2: Toxic substances ingested by patients.

|                              | Charcoal-available period | Charcoal-unavailable period |
|------------------------------|---------------------------|----------------------------|
| CNS Affecting Drug, n (%) *  | 134 (32.4%)               | 77 (34.8%)                 |
| Benzodiazepine, n (%)        | 21 (5.1%)                 | 8 (3.6%)                  |
| Acetaminophen, n (%)         | 16 (3.9%)                 | 8 (3.6%)                  |
| Cardiovascular drug, n (%)   | 4 (1.0%)                  | 4 (1.8%)                  |
| Salicylate, n (%)            | 6 (1.5%)                  | 1 (0.5%)                  |
| OTC drugs, n (%) †           | 9 (2.2%)                  | 7 (3.2%)                  |
| Two or more toxin types, n (%)| 132 (32.0%)             | 73 (33.0%)                 |
| Others, n (%)                | 51 (12.3%)                | 26 (11.8%)                |
| Unknown, n (%)               | 40 (9.7%)                 | 17 (7.7%)                 |

CNS: central nervous system; OTC: over the counter.

* Except benzodiazepine.

† Substances not clearly identified.
Table 3: Charcoal availability and clinical outcome.

| Charcoal-available period | Charcoal-unavailable period | p-value |
|---------------------------|-----------------------------|---------|
| Aspiration pneumonia, n (%) | 41 (9.9%) | 21 (9.5%) | 0.864 |
| Endotracheal intubation, n (%) | 35 (8.5%) | 16 (7.2%) | 0.586 |
| Vasopressor, n (%) | 22 (5.3%) | 11 (5.0%) | 0.850 |
| Mortality, n (%) | 8 (1.9%) | 2 (0.9%) | 0.507 |
| Hospital admission, n (%) | 179 (43.3%) | 66 (29.9%) | <0.001 |
| ICU admission, n (%) | 24 (5.8%) | 30 (13.6%) | <0.001 |

ICU: intensive care unit.

Table 4: GCS and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

| Charcoal-available period | Charcoal-unavailable period | p-value | Charcoal-unavailable period | p-value |
|---------------------------|-----------------------------|---------|-----------------------------|---------|
| **Aspiration pneumonia** |                             |         |                             |         |
| Non-charcoal              | Charcoal-available period   |         | Charcoal-unavailable period |         |
| GCS 13-15                 | 7 (4.0%)                    | 7 (7.4%) | 14 (5.2%)                   | 0.258   | 3 (2.1%) | 0.119 |
| GCS 9-12                  | 7 (13.7%)                   | 3 (10.7%) | 10 (12.7%)                  | >0.990 | 4 (10.8%) | >0.999 |
| GCS 3-8                   | 14 (29.2%)                  | 3 (15.8%) | 17 (25.4%)                  | 0.356   | 14 (36.8%) | 0.216 |
| **Intubation**            |                             |         |                             |         |
| GCS 13-15                 | 3 (1.7%)                    | 6 (6.4%) | 9 (3.4%)                    | 0.071   | 3 (2.1%) | 0.552 |
| GCS 9-12                  | 5 (9.8%)                    | 4 (14.3%) | 9 (11.4%)                   | 0.713   | 3 (8.1%) | 0.749 |
| GCS 3-8                   | 9 (18.8%)                   | 8 (47.1%) | 17 (25.4%)                  | 0.064   | 10 (26.3%) | 0.915 |
| **Vasopressor use**       |                             |         |                             |         |
| GCS 13-15                 | 7 (4.0%)                    | 3 (3.2%) | 10 (3.7%)                   | >0.990 | 5 (3.4%) | 0.868 |
| GCS 9-12                  | 4 (7.8%)                    | 1 (3.6%) | 5 (6.3%)                    | 0.651   | 1 (2.7%) | 0.663 |
| GCS 3-8                   | 6 (12.5%)                   | 1 (5.3%) | 7 (10.4%)                   | 0.663   | 5 (13.2%) | 0.753 |
| **Mortality**             |                             |         |                             |         |
| GCS 13-15                 | 3 (1.7%)                    | 1 (1.1%) | 4 (1.5%)                    | >0.990 | 1 (0.7%) | 0.660 |
| GCS 9-12                  | 1 (2.0%)                    | 0 (0%)   | 1 (1.3%)                    | >0.990 | 1 (2.7%) | 0.538 |
| GCS 3-8                   | 3 (6.3%)                    | 0 (0%)   | 3 (4.5%)                    | 0.553   | 0 (0%)   | 0.552 |
| **Hospital admission**    |                             |         |                             |         |
| GCS 13-15                 | 50 (28.9%)                  | 39 (41.5%) | 89 (33.3%)                  | 0.037   | 28 (19.2%) | 0.002 |
| GCS 9-12                  | 26 (51.0%)                  | 17 (60.7%) | 43 (54.4%)                  | 0.046   | 15 (40.5%) | 0.163 |
| GCS 3-8                   | 36 (75.6%)                  | 11 (57.9%) | 47 (70.1%)                  | 0.168   | 23 (60.5%) | 0.315 |
| **ICU admission**         |                             |         |                             |         |
| GCS 13-15                 | 2 (1.2%)                    | 6 (6.4%) | 8 (3.0%)                    | 0.024   | 12 (8.2%) | 0.028 |
| GCS 9-12                  | 3 (5.9%)                    | 2 (71%)  | 5 (6.3%)                    | >0.990 | 6 (16.2%) | 0.102 |
| GCS 3-8                   | 7 (14.6%)                   | 4 (21.1%) | 11 (16.4%)                  | 0.492   | 12 (31.6%) | 0.071 |
| **Number of patients**    |                             |         |                             |         |
| GCS 13-15                 | 173                         | 94       | 267                         | 146     |
| GCS 9-12                  | 51                          | 28       | 79                          | 37      |
| GCS 3-8                   | 48                          | 19       | 67                          | 38      |

GCS: Glasgow Coma Scale; ICU: intensive care unit.

*Between non-charcoal and charcoal.
†Between charcoal-available and charcoal-unavailable periods.

(Table 8). Other patients visited the ED 4 hours or more after exposure to toxins (Table 8).

4. Discussion

Activated charcoal has been used for the treatment of poisoned patients for more than 100 years and remains the major GI decontamination therapy for such cases [1, 2, 5, 14]. Many preclinical studies have shown beneficial effects of activated charcoal in various kinds of drug poisonings [5, 15–19]. However, few clinical studies have established any clinical benefits of activated charcoal use [1, 2, 5, 14]. One retrospective study showed activated charcoal within 2 hours of a paracetamol ingestion is associated with a decreased requirement for N-acetylcysteine [20]. A recent prospective study on massive paracetamol overdose found a benefit of activated charcoal use within 4 hours.
Table 5: Multiple-drug ingestion and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

|                      | Charcoal-available period | Charcoal-unavailable period | p-value†   |
|----------------------|---------------------------|----------------------------|------------|
| **Aspiration pneumonia** |                           |                            |            |
| single drug          | 11 (9.9%)                 | 8 (13.3%)                  | 0.497      |
| multiple drug        | 17 (10.6%)                | 5 (6.2%)                   | 0.263      |
| Intubation            |                           |                            |            |
| single drug          | 8 (7.2%)                  | 9 (15.0%)                  | 0.104      |
| multiple drug        | 9 (5.6%)                  | 9 (11.1%)                  | 0.122      |
| Vasopressor use       |                           |                            |            |
| single drug          | 5 (4.5%)                  | 1 (1.7%)                   | 0.666      |
| multiple drug        | 12 (7.5%)                 | 4 (4.9%)                   | 0.588      |
| **Mortality**         |                           |                            |            |
| single drug          | 3 (2.7%)                  | 0 (0%)                     | 0.553      |
| multiple drug        | 4 (2.5%)                  | 1 (1.2%)                   | 0.667      |
| Hospital admission    |                           |                            |            |
| single drug          | 49 (44.1%)                | 30 (50.0%)                 | 0.464      |
| multiple drug        | 63 (39.1%)                | 37 (45.7%)                 | 0.329      |
| ICU admission         |                           |                            |            |
| single drug          | 2 (1.8%)                  | 7 (11.7%)                  | 0.010      |
| multiple drug        | 10 (6.2%)                 | 5 (6.2%)                   | 0.991      |
| Number of patients   |                           |                            |            |
| single drug          | 111                       | 60                         | 171        |
| multiple drug        | 161                       | 81                         | 242        |

GCS: Glasgow Coma Scale; ICU: intensive care unit.

* Between noncharcoal and charcoal.
† Between charcoal-available and charcoal-unavailable period.

Figure 1: Length of stay of patients admitted to ICU between charcoal-available and charcoal-unavailable periods. * One extreme outlier case is present in charcoal-unavailable period (41 ICU days and 91 total hospital days).
Table 6: Time delay from drug ingestion to ED visit and clinical outcome between charcoal-available and charcoal-unavailable periods.

|                      | Non-charcoal | Charcoal-available period | Charcoal-unavailable period | p-value* | p-value† |
|----------------------|--------------|----------------------------|----------------------------|----------|----------|
|                      | Total        |                            |                            |          |          |
| Aspiration pneumonia | 8 (7.3%)     | 5 (7.6%)                   | 3 (6.8%)                   | 1        | 5 (7.8%) |
| within 1 hr          |              |                            |                            |          |          |
|                      | 23 (11.2%)   | 10 (10.3%)                 | 10 (10.9%)                 | 0.823    | >0.999   |
| over 1 hr            | 6 (9.1%)     | 5 (11.4%)                  | 11 (10%)                   | 0.015    | 0.214    |
| Intubation           | 11 (5.3%)    | 13 (13.4%)                 | 24 (7.9%)                  | 0.697    | 0.893    |
| Vasopressor use      | 1 (1.5%)     | 0 (0%)                     | 1 (0.9%)                   | 1        | 3 (4.7%) |
| within 1 hr          | 16 (7.8%)    | 5 (5.2%)                   | 21 (6.9%)                  | 0.404    | 0.443    |
| over 1 hr            |              |                            |                            |          |          |
| Mortality            | 7 (3.4%)     | 1 (1.0%)                   | 8 (2.6%)                   | 0.231    | 2 (1.3%) |
| within 1 hr          |              |                            |                            |          |          |
| Hospital admission   | 17 (25.8%)   | 20 (45.5%)                 | 37 (33.6%)                 | 0.339    | 15 (23.4%) |
| over 1 hr            | 95 (46.1%)   | 47 (48.5%)                 | 142 (46.9%)                | 0.171    | 51 (32.5%) |
| ICU admission        | 3 (4.5%)     | 4 (9.1%)                   | 7 (6.4%)                   | 0.434    | 7 (10.9%) |
| within 1 hr          | 9 (4.4%)     | 8 (8.2%)                   | 17 (5.6%)                  | 0.171    | 23 (14.6%) |
| over 1 hr            |              |                            |                            |          |          |
| Number of patients   | 66           | 44                         | 110                        |          |          |
| within 1 hr          | 206          | 97                         | 303                        |          |          |
| over 1 hr            |              |                            |                            |          |          |

GCS: Glasgow Coma Scale; ICU: intensive care unit.
* between noncharcoal and charcoal.
† Between charcoal-available and charcoal-unavailable period.

Table 7: Clinical outcomes of patients who may benefit from activated charcoal use*.

|                      | Charcoal-available period | Charcoal-unavailable period | p-value |
|----------------------|---------------------------|-----------------------------|---------|
|                      | n=23                      | n=17                        |         |
| Aspiration pneumonia | 2 (8.7%)                  | 1 (5.9%)                    | 0.615   |
| Endotracheal intubation | 1 (4.3%)                    | 1 (5.9%)                    | >0.999  |
| Endotracheal intubation after 4 hours from ED visit, n (%) | 1 (4.3%) | 0 (0%) | >0.999 |
| Vasopressor, n (%)   | 0 (0%)                    | 2 (11.8%)                   | 0.174   |
| Vasopressor after 4 hours from ED visit, n (%) | 0 (0%) | 1 (5.9%) | 0.436 |
| Mortality, n (%)     | 0 (0%)                    | 0 (0%)                      | NA      |
| Hospital admission, n (%) | 8 (34.8%)                | 5 (29.4%)                   | 0.072   |
| ICU admission, n (%) | 1 (4.3%)                  | 3 (17.6%)                   | 0.294   |
| Prolonged ICU admission | 1 (4.3%)                    | 1 (5.9%)                    | >0.999  |

ICU: intensive care unit.
* : (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion.

that time, development of hepatotoxicity (peak ALT > 1000 U/L) was lower in the charcoal-treated patients. However, only serum liver enzyme levels were evaluated as an outcome and mortality, hospital day, presence and severity of hepatic encephalopathy, and liver transplantation were not [21].

Various clinical studies have failed to prove any clinical benefits of activated charcoal [8, 13, 22–24]. In a prospective ED study, there was no improvement of the clinical outcomes of single-dose activated charcoal. Activated charcoal use was associated with longer ED stay and higher incidence of vomiting. However, ICU admission, length of ICU and
hospital stay, length of intubation time, and development of aspiration pneumonia were found to be unrelated to activated charcoal use [13]. One recent prospective study showed that age was the only factor associated with clinical improvement in case of drug poisoning, activated charcoal administration was determined to be unrelated to clinical outcome [24].

The reasons for the discrepancies between the results of preclinical and clinical studies are not clear. The risk of charcoal-induced aspiration might be one explanation. Chemical pneumonitis due to direct charcoal exposure is a fatal complication and has been, to say the least, a major concern [5, 25–29]. Development of aspiration pneumonitis in overdose patients has been related to poor prognosis [10, 11]. Activated charcoal use in instance of nonintubation and decreased mental status has been related to aspiration pneumonia [10]. However, other clinical studies have shown minimal risk of aspiration pneumonitis and pneumonia in the use of activated charcoal [30–32]. One retrospective study found that the incidence of pulmonary aspiration was only 0.6% in patients who had received multiple doses of activated charcoal [30]. An analysis of a toxicology-unit admission cohort showed a prevalence of aspiration pneumonitis of 11% and established that the predictors did not include activated charcoal use but rather age, emesis, and time delay from ingestion to hospital [32].

It is well known that airway protection is important for prevention of aspiration pneumonitis in poisoned patients [9]. The current guidelines emphasize airway protection prior to activated charcoal use [1, 2, 5]. In our study, intubations also were conducted more frequently for charcoal-administered patients (18, 51.4%) than for not-administered patients (17, 6.3%) (p = 0.024) in the charcoal-available period.

In our study, mortality, need of vasopressor, intubation, and incidence of aspiration pneumonia were not affected by charcoal availability (Table 3). Within the charcoal-available period, aspiration pneumonia developed in 13 (9.2%) of the charcoal-administered patients and 28 (10.3%) of the not-administered patients, of which difference was not significant (p = 0.729).

The ICU admission rate was increased in the charcoal-unavailable period (5 [3–10] versus 2 [1–5], p = 0.010 and, 10 [4–19] versus 4 [3–9], p = 0.021, respectively) (Figure 1). Because ICU days were shorter in the charcoal-unavailable period, the increase in the ICU admission rate might have been the result of concerns about activated charcoal unavailability.

In our study, most of the deaths occurred when the visit to the ED was delayed (Table 8). Delayed ED presentation can cause worsening of poisoning [33]. Early adequate supportive care seems to be a more cardinal treatment process than activated charcoal use.

The rate of activated charcoal use was high in charcoal-available period (34.1%). Nearly half (42%) of patients received the activated charcoal more than 2 hours after exposure to toxins. A Norwegian study reported 16% activated charcoal use for all admitted acute-poisoning patients in Oslo [34, 35]. However, our study also showed a low mortality rate in both the charcoal-available and charcoal-unavailable periods. These findings indirectly show that adequate supportive care is essential to the treatment of oral drug poisoned patients.

There are several limitations to this study. First, it is a retrospective study. Neither randomization nor nor blinding was applied, and clinical decisions might have been affected by charcoal-availability. Second, the severity of poisoning was not high; the total mortality was only 1.6% (10 patients). Considering that activated charcoal is more beneficial for severe poisoning, its effect might have been underestimated [1, 2]. High mortality was observed among the delayed ED visit patients. Third, we included only adult patients and oral drug poisonings other than from plants, mushrooms, herbicides, and pesticides. Fourth, gastric lavage was used as a GI decontaminating agent in both periods and which can attenuate the clinical effects of charcoal unavailability. Finally, the exact substances or amounts could not be identified in many cases and thus were not fully evaluated in this study.

### 5. Conclusions

Between the charcoal-available and charcoal-unavailable periods, activated charcoal availability was unrelated to mortality, incidence of aspiration pneumonia, intubation, or use of vasopressor for treatment of oral drug poisoned patients.

---

**Table 8: Summary of mortality cases.**

| Period              | Sex | Age | Activated charcoal use | Time delay | Survival time | Toxic substances               |
|---------------------|-----|-----|------------------------|------------|--------------|--------------------------------|
| Charcoal-available  | male| 92  | -                      | 2 hours    | 18 days      | Sedatives                      |
| Charcoal-available  | female| 78 | -                      | 4 hours    | 2 days       | Unidentified                   |
| Charcoal-available  | male| 29  | -                      | 17 hours   | 16 hours     | Salicylate                     |
| Charcoal-available  | female| 66 | -                      | 8 hours    | 12 hours     | Antidepressants                |
| Charcoal-available  | female| 17 | -                      | 7 hours    | 7 hours      | Bupropion                      |
| Charcoal-available  | male| 72  | -                      | 12 hours   | 1 days       | Antipsychotics                 |
| Charcoal-available  | female| 70 | -                      | 6 hours    | 12 hours     | Multiple drug including betablocker |
| Charcoal-available  | male| 56  | +                      | 4 hours    | 10 days      | Multiple unidentified drugs including sedatives |
| Charcoal-unavailable | male| 77  | -                      | 6 hours    | 4 days       | Multiple antipsychotics        |
| Charcoal-unavailable | male| 61  | -                      | 4 hours    | 3 days       | Unknown                        |
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

None of the authors has any financial or personal relationships with people or organizations that could inappropriately influence this study.

Supplementary Materials

Supplemental Table 1: time delay from drug exposure to presentation. Supplemental Table 2: major toxic agents of patients who may benefit from activated charcoal*. NSAID: Nonsteroidal Anti-Inflammatory Drugs. *: (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion. (Supplementary Materials)

References

[1] K. R. Olson, “Activated charcoal for acute poisoning: one toxicologist’s journey,” Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, vol. 6, no. 2, pp. 190–198, 2010.
[2] G. K. Isbister and V. V. Kumar, “Indications for single-dose activated charcoal administration in acute overdose,” Current Opinion in Critical Care, vol. 17, no. 4, pp. 351–357, 2011.
[3] E. M. Caravati and B. Mégarbane, “Update of position papers on gastrointestinal decontamination for acute overdose,” Clinical Toxicology, vol. 51, no. 3, pp. 127-127, 2013.
[4] D. D. Gummrin, J. B. Mowry, D. A. Spyker, D. E. Brooks, M. O. Fraser, and W. Banner, “2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report,” Clinical Toxicology, vol. 55, no. 10, pp. 1072–1254, 2017.
[5] P. A. Chyka and D. Seger, “Position paper: single-dose activated charcoal,” Journal of Toxicology, vol. 43, no. 2, pp. 61–87, 2005.
[6] S. M. Reid, G. M. Neto, T. J. Clifford, N. Randhawa, and A. Plint, “Use of single-dose activated charcoal among Canadian pediatric emergency physicians,” Pediatric Emergency Care, vol. 22, no. 10, pp. 724–728, 2006.
[7] G. Corcoran, B. Chan, and A. Chiew, “Use and knowledge of single dose activated charcoal: A survey of Australian doctors,” EMA - Emergency Medicine Australasia, vol. 28, no. 5, pp. 578–585, 2016.
[8] J. Moon, B. Chun, and K. Song, “An exploratory study; the therapeutic effects of premixed activated charcoal–sorbitol administration in patients poisoned with organophosphate pesticide,” Clinical Toxicology, vol. 53, no. 2, pp. 119–126, 2015.
[9] J. Moll, W. Kerns II, C. Tomaszewski, and R. Rose, “Incidence of aspiration pneumonia in intubated patients receiving activated charcoal,” The Journal of Emergency Medicine, vol. 17, no. 2, pp. 279–283, 1999.
[10] J. Liisunantti, P. Kaukoranta, M. Martikainen, and T. Ala-Kokko, “Aspiration pneumonia following severe self-poisoning,” Resuscitation, vol. 56, no. 1, pp. 49–53, 2003.
[11] A. Christ, C. A. Arranto, C. Schindler et al., “Incidence, risk factors, and outcome of aspiration pneumonitis in ICU overdose patients,” Intensive Care Medicine, vol. 32, no. 9, pp. 1423–1427, 2006.
[12] S. Beauchet, P. Juvet, A. Beauchet, E. Casalino, and B. Megarbane, “Deliberate drug poisonings admitted to an emergency department in Paris area - A descriptive study and assessment of risk factors for intensive care admission,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 6, pp. 1174–1179, 2016.
[13] K. S. Merigian and K. E. Blaho, “Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial,” American Journal of Therapeutics, vol. 9, no. 4, pp. 301–308, 2002.
[14] D. N. Juurlink, “Activated charcoal for acute overdose: a reappraisal,” British Journal of Clinical Pharmacology, vol. 81, no. 3, pp. 482–487, 2016.
[15] G. R. Bond, “The role of activated charcoal and gastric emptying in gastrointestinal decontamination: A state-of-the-art review,” Annals of Emergency Medicine, vol. 39, no. 3, pp. 273–286, 2002.
[16] W. N. Glab, D. G. Corby, W. J. Decker, and V. R. Coldiron, “Decreased absorption of propoxyphene by activated charcoal,” Clinical Toxicology, vol. 19, no. 2, pp. 129–138, 1982.
[17] A. L. Picchioni, L. Chin, and T. Gillespie, “Evaluation of activated charcoal-sorbitol suspension as an antidote,” Clinical Toxicology, vol. 19, no. 5, pp. 433–444, 1982.
[18] G. Jürgens, L. C. Groth Hoeberg, and N. A. Graudal, “The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis,” Clinical Pharmacology & Therapeutics, vol. 85, no. 5, pp. 501–505, 2009.
[19] M. Mullins, B. R. Froelke, and M. R.-P. Rivera, “Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen,” Clinical Toxicology, vol. 47, no. 2, pp. 112–115, 2009.
[20] N. A. Buckley, I. M. Whyte, D. L. O’Connell, and A. H. Dawson, “Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose,” Journal of Toxicology - Clinical Toxicology, vol. 37, no. 6, pp. 753–757, 1999.
[21] A. L. Chiew, G. K. Isbister, K. A. Kirby, C. B. Page, B. S. H. Chan, and N. A. Buckley, “Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2),” Clinical Toxicology, vol. 55, no. 10, pp. 1055–1065, 2017.
[22] M. Edelsten, E. Juszczak, N. A. Buckley et al., “Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial,” The Lancet, vol. 371, no. 9612, pp. 579–587, 2008.
[23] K. Cumpston, P. Stromberg, B. K. Wills, and S. R. Rose, “Activated charcoal does not reduce duration of phenytoin toxicity in hospitalized patients,” American Journal of Therapeutics, vol. 23, no. 3, pp. c773–c777, 2016.
[24] G. Orfanidou, A. Chalkias, A. Koutsovasilis, G. Loizos, and T. Xanthos, “Activated charcoal may not be necessary in all oral overdoses of medication,” The American Journal of Emergency Medicine, vol. 34, no. 2, pp. 319–321, 2016.
[25] D. G. Menzies, A. Busuttil, and L. F. Prescott, “Fatal pulmonary aspiration of oral activated charcoal,” BMJ, vol. 297, no. 6646, pp. 459–460, 1988.
[26] C. G. Elliott, T. V. Colby, T. M. Kelly, and H. G. Hicks, “Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal,” CHEST, vol. 96, no. 3, pp. 672–674, 1989.
[27] A. De Weerdt, A. Snoeckx, P. Germonpré, and P. G. Jorens, “Rapid-onset adult respiratory distress syndrome after activated charcoal ingestion,” Intensive Care Medicine, vol. 32, no. 9, pp. 1423–1427, 2006.
charcoal aspiration. A pitch-black tale of a potential to kill,” *American Journal of Respiratory and Critical Care Medicine*, vol. 191, no. 3, pp. 344-345, 2015.

[28] C. R. Harris and D. Filandrinos, “Accidental administration of activated charcoal into the lung: Aspiration by proxy,” *Annals of Emergency Medicine*, vol. 22, no. 9, pp. 1470–1473, 1993.

[29] J. B. Hack, M. Gilliland, and W. J. Meggs, “Imagery in emergency medicine,” *Annals of Emergency Medicine*, vol. 48, no. 5, p. 522, 2006.

[30] C. L. Dorrington, D. W. Johnson, and R. Brant, “The frequency of complications associated with the use of multiple-dose activated charcoal,” *Annals of Emergency Medicine*, vol. 41, no. 3, pp. 370–377, 2003.

[31] A. O. Alaspää, M. J. Kuisma, K. Hoppu, and P. J. Neuvonen, “Out-of-hospital administration of activated charcoal by emergency medical services,” *Annals of Emergency Medicine*, vol. 45, no. 2, pp. 207–212, 2005.

[32] G. K. Isbister, F. Downes, D. Sibbritt, A. H. Dawson, and I. M. Whyte, “Aspiration pneumonitis in an overdose population: Frequency, predictors, and outcomes,” *Critical Care Medicine*, vol. 32, no. 1, pp. 88–93, 2004.

[33] D. G. Craig, C. M. Bates, J. S. Davidson, K. G. Martin, P. C. Hayes, and K. J. Simpson, “Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity,” *British Journal of Clinical Pharmacology*, vol. 73, no. 2, pp. 285–294, 2012.

[34] C. Lund, P. Drottning, B. Stiksrud et al., “A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae,” *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, vol. 20, article no. 49, 2012.

[35] C. Lund, B. Teige, P. Drottning et al., “A one-year observational study of all hospitalized and fatal acute poisonings in Oslo: Epidemiology, intention and follow-up,” *BMC Public Health*, vol. 12, no. 1, 2012.